Assessment of the clinical utility of pharmacogenetic guidance in a comprehensive medication management service.

摘要: Introduction Pharmacists are poised to be the health care professionals best suited provide medication-related consults and services based on a patient's genetics. Despite its potential benefits, implementation of pharmacogenetic (PGx) testing into primary clinical settings has been slow among medically underserved populations. To our knowledge, this is first time that PGx-driven recommendations have incorporated Comprehensive Medication Management (CMM) service in Hispanic population. Objectives The aim study evaluate utility adding PGx guidance pharmacist-driven CMM. Methods This pre- post-interventional design study. Patients were recruited from psychologist's clinic. A total 24 patients had face-to-face interview with pharmacist complete CMM, Personal Record, Medication-Related Action Plan (MAP) blind findings. Collected buccal DNA samples genotyped using drug-metabolizing enzymes transporters (DMET) Plus Array. Results generated new MAPs for each patient results. Genetic variants could potentially affect safety effectiveness at least one drug pharmacotherapy identified 96% patients, whom changed initial recommendations. Polymorphisms genes encoding isoenzymes CYP2D6, CYP2C19, CYP2C9 83%, 52%, 41% respectively. performing CMM 22 additional medication problems after determinations. Moreover, they agreed studied sample perceived value traditional decision-making process pharmacists. Conclusions confirmed critical role played by pharmacists facilitating usage relevant genetic information optimize therapy decisions as well their involvement many levels these multidisciplinary efforts, including championing leading PGx-guided services.